Investor Overview

Latest News Releases

2022 Annual Report

Neurocrine Biosciences has four commercial, FDA-approved treatments in the United States and a robust pipeline.

Annual Reports

Stock Quote

(Common Stock)

Change
Volume
52 Week High
52 Week Low

10/06/23 10:52 PM EDT

Data Provided by Refinitiv. Minimum 15 minutes delayed

Latest Filings

Filing date	Form	Description	Filing Group	View
02/08/10	10-K	Annual report which provides a comprehensive overview of the company for the past year	Annual Filings	View HTML 0001193125-10-023586.pdf 0001193125-10-023586.rtf 0001193125-10-023586.xls
02/07/06	10-K	Annual report which provides a comprehensive overview of the company for the past year	Annual Filings	View HTML 0000936392-06-000084.pdf 0000936392-06-000084.rtf 0000936392-06-000084.xls
03/15/04	10-K	Annual report which provides a comprehensive overview of the company for the past year	Annual Filings	View HTML 0000936392-04-000211.pdf 0000936392-04-000211.rtf 0000936392-04-000211.xls

Data provided by Kaleidoscope.

Corporate Sustainability

Our ESG programs are aligned to our purpose, which we fulfill
through effective management of critical environmental, social, and
governance principles that are fundamental to our business.

2022 ESG Report